Vivienne A Ayomanor, NP
Nurse Practitioner · Los Angeles
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 9 years
- Graduated 2017
Offices
1 location · St. John'S Community Health · 151 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Vivienne A Ayomanor’s office at (323) 541-1600 to ask if they take your plan before you enroll.
Medicaid work
$54,736 in 2024
Medicaid paid $54,736 for 724 billed services this clinician did in 2024, up to 40 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 249 | $46,717 |
| Short return visit (20+ min) | 347 | $8,020 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 39 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 76 | $0 |
| Annual depression screening, 5 to 15 minutes | 13 | $0 |
| 2024 | 724 | 5 | 40 | $54,736 |
| 2023 | 1,096 | 8 | 37 | $39,694 |
| 2022 | 4,628 | 14 | 106 | $116,560 |
| 2021 | 6,681 | 20 | 141 | $215,944 |
| 2020 | 6,679 | 16 | 157 | $256,754 |
| 2019 | 2,328 | 7 | 82 | $120,481 |
| 2018 | 525 | 1 | 55 | $64,807 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 198 | $39,204 |
| Short return visit (20+ min) | 369 | $457 |
| Screening performed and negative | 91 | $29 |
| Bilateral quantitative screening test of visual acuity | 68 | $4 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 114 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 204 | $0 |
| Initial comprehensive preventive medicine evaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; adolescent (age 12 through 17 years) | 36 | $0 |
| Alcohol and/or drug services, brief intervention, per 15 minutes | 16 | $0 |
2022
| Clinic visit/encounter, all-inclusive | 653 | $115,166 |
| Short return visit (20+ min) | 1,195 | $1,344 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 121 | $25 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 115 | $25 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 717 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 100 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 169 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 836 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 190 | $0 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 185 | $0 |
| Blood test, lipids (cholesterol and triglycerides) | 296 | $0 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 18 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 1,222 | $214,465 |
| Short return visit (20+ min) | 1,503 | $1,371 |
| Short return visit | 172 | $107 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose | 40 | $0 |
| Discharge medications reconciled with the current medication list in outpatient medical record (COA) (GER) | 12 | $0 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 1,189 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 96 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 59 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 1,472 | $0 |
| Most recent diastolic blood pressure 80-89 mm Hg (HTN, CKD, CAD) (DM) | 14 | $0 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 179 | $0 |
| Blood test, lipids (cholesterol and triglycerides) | 293 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 1,448 | $254,234 |
| Short return visit (20+ min) | 1,750 | $2,520 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 1,085 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 14 | $0 |
| Most recent systolic blood pressure greater than or equal to 140 mm Hg (HTN, CKD, CAD) (DM) | 38 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 1,244 | $0 |
| COLLECTION VENOUS BLOOD VENIPUNCTURE | 67 | $0 |
| Blood test, lipids (cholesterol and triglycerides) | 219 | $0 |
| Blood glucose (sugar) level | 13 | $0 |
| BLOOD COUNT PLATELET AUTOMATED | 12 | $0 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use | 42 | $0 |
| Handling and/or conveyance of specimen for transfer from physician office to laboratory | 229 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 919 | $120,481 |
| Most recent systolic blood pressure less than 130 mm Hg (DM) (HTN, CKD, CAD) | 377 | $0 |
| Most recent systolic blood pressure 130-139 mm Hg (DM) (HTN, CKD, CAD) | 12 | $0 |
| Most recent diastolic blood pressure less than 80 mm Hg (HTN, CKD, CAD) (DM) | 442 | $0 |
| Blood test, lipids (cholesterol and triglycerides) | 53 | $0 |
| Short return visit | 14 | $0 |
| Short return visit (20+ min) | 511 | $0 |
2018
| Clinic visit/encounter, all-inclusive | 525 | $64,807 |
Drugs they prescribed that Part D paid
$57,306
Pharmacies billed $57,306 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 210) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
191 generic and fewer than 11 brand-name prescriptions · $57,306 in drug cost · 18 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Naltrexone | 22 | $597 | $27 |
| Bupropion Hcl Sr | 15 | $103 | $7 |
| Buspirone | 11 | $73 | $7 |
| Sertraline | 11 | $20 | $2 |
Year by year
| 2024 | 210 | 42 | 0% (0) | None | $57,306 |
| 2023 | 92 | 31 | 0% (0) | None | $20,654 |
| 2022 | 252 | 50 | 0% (0) | None | $28,320 |
| 2021 | 225 | 45 | 0% (0) | None | $12,079 |
| 2020 | 196 | 46 | 0% (0) | None | $15,806 |
| 2019 | 279 | 64 | 0% (0) | None | $22,013 |
| 2018 | 68 | 24 | 0% (0) | None | $6,407 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Lisinopril | 11 | $179 | $16 |
| Metformin | 12 | $127 | $11 |
2022: 6 drugs
| Lisinopril | 36 | $439 | $12 |
| Losartan | 15 | $290 | $19 |
| Amlodipine Besylate | 28 | $264 | $9 |
| Atorvastatin | 15 | $214 | $14 |
| Metformin | 16 | $213 | $13 |
| Hydrochlorothiazide | 13 | $63 | $5 |
2021: 7 drugs
| Atorvastatin | 19 | $296 | $16 |
| Metformin | 15 | $147 | $10 |
| Lisinopril | 16 | $134 | $8 |
| Amlodipine Besylate | 20 | $112 | $6 |
| Losartan | 11 | $112 | $10 |
| Gabapentin | 12 | $77 | $6 |
| Hydrochlorothiazide | 13 | $35 | $3 |
2020: 3 drugs
| Amlodipine Besylate | 17 | $138 | $8 |
| Lisinopril | 17 | $88 | $5 |
| Metformin | 15 | $87 | $6 |
2019: 7 drugs
| Atorvastatin | 16 | $228 | $14 |
| Metformin | 22 | $149 | $7 |
| Lisinopril | 27 | $141 | $5 |
| Losartan | 11 | $103 | $9 |
| Simvastatin | 12 | $94 | $8 |
| Amlodipine Besylate | 11 | $76 | $7 |
| Hydrochlorothiazide | 12 | $42 | $4 |
Money from drug and device companies
$1,118 in 2025
| 2025 | 5 | 16 | None | $1,118 |
| 2024 | 11 | 36 | None | $2,698 |
| 2023 | 8 | 29 | None | $1,942 |
| 2022 | 2 | 3 | None | $259 |
| 2021 | 1 | 1 | None | $114 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Pharmaceuticals | Invega Sustenna | $750 | 10 payments
|
| Teva Pharmaceuticals USA | Uzedy | $174 | 2 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $113 | 1 payment
|
| Indivior | Sublocade | $67 | 2 payments
|
| Gilead Sciences | None | $14 | 1 payment
|
See all 16 published payments
| Otsuka America Pharmaceutical | Meals · 2025-11-09 | Abilify Maintena | $113 |
| Janssen Pharmaceuticals | Meals · 2025-09-05 | Invega Sustenna | $134 |
| Gilead Sciences | Meals · 2025-09-02 | None | $14 |
| Janssen Pharmaceuticals | Meals · 2025-07-31 | Invega Sustenna | $18 |
| Janssen Pharmaceuticals | Meals · 2025-06-12 | Invega Sustenna | $30 |
| Janssen Pharmaceuticals | Meals · 2025-06-04 | Invega Sustenna | $134 |
| Indivior | Meals · 2025-05-21 | Sublocade | $35 |
| Teva Pharmaceuticals USA | Meals · 2025-05-21 | Uzedy | $121 |
| Janssen Pharmaceuticals | Meals · 2025-04-30 | Invega Sustenna | $137 |
| Janssen Pharmaceuticals | Meals · 2025-04-17 | Spravato | $106 |
| Janssen Pharmaceuticals | Meals · 2025-03-27 | Invega Sustenna | $32 |
| Indivior | Meals · 2025-03-12 | Sublocade | $32 |
| Teva Pharmaceuticals USA | Meals · 2025-03-09 | Uzedy | $54 |
| Janssen Pharmaceuticals | Meals · 2025-03-05 | Invega Sustenna | $119 |
| Janssen Pharmaceuticals | Meals · 2025-02-20 | Invega Sustenna | $20 |
| Janssen Pharmaceuticals | Meals · 2025-01-09 | Invega Sustenna | $21 |
See earlier years (2024, 2023, 2022, 2021)
2024: $2,698
| Janssen Pharmaceuticals | Invega Sustenna | $738 | 14 payments
|
| Abbvie | Mavyret | $430 | 6 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $363 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $248 | 2 payments
|
| Teva Pharmaceuticals USA | Uzedy | $181 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $158 | 1 payment
|
| Mayne Pharma Commercial | Nextstellis | $125 | 1 payment
|
| ViiV Healthcare | None | $124 | 1 payment
|
| Otsuka America Pharmaceutical | Rexulti | $122 | 1 payment
|
| Braeburn | Brixadi | $111 | 1 payment
|
| Indivior | Sublocade | $99 | 4 payments
|
2023: $1,942
| Janssen Pharmaceuticals | Invega Sustenna | $717 | 14 payments
|
| Hologic Sales and Service | Aptima | $277 | 2 payments
|
| Iti | Caplyta | $241 | 2 payments
|
| Teva Pharmaceuticals USA | Uzedy | $190 | 2 payments
|
| Neurocrine Biosciences | Ingrezza | $144 | 1 payment
|
| Alkermes | Vivitrol | $132 | 5 payments
|
| Abbvie | Vraylar | $123 | 2 payments
|
| Exact Sciences | Cologuard Collection Kit | $117 | 1 payment
|
2022: $259
| Alkermes | Lybalvi | $141 | 2 payments
|
| Teva Pharmaceuticals USA | Austedo | $118 | 1 payment
|
2021: $114
| Neurocrine Biosciences | Ingrezza | $114 | 1 payment
|
Professional record
- NPI
- 1790282960
- Licence
- CA F03180872
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 364SP0810X (364SP0810X); Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 12235 Dune St, Norwalk, CA, 90650
- NPI first listed
- 2018-04-12
- NPI last updated
- 2025-10-30
- NPI record certified
- 2025-10-30
This is when the NPI record was last certified, not a medical board exam.